I50
Conditions
Interventions
Group 1: 1. Inclusion as part of the inpatient stay or an outpatient presentation (initial SARS-Cov 2 proof = 7 days) or at planned outpatient follow-up (<= 3 months) (only in patients with a clinical
Sponsors
Universitätsklinik für Pneumologie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients in the final isolated stage of SARS-CoV-2 infection 2. Patients with sinus rhythm or patients with paroxysmal atrial fibrillation 3. Patient is able to obtain a Holter ECG 4. Signed Consent Form
Exclusion criteria
Exclusion criteria: 1. Patients with persistent or permanent atrial fibrillation 2. Patients who require permanent atrial pacing an HSM 3. Age < 18 years 4. Pregnancy or lactating 5. State after cardiac transplantation (HTX) 6. Chronic renal failure patients with stages 4 and 5 according to KDOQI 7. Patients with active tumor diseases undergoing chemotherapy/radiation therapy 8. Therapy with topical corticosteroid therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Collection of reference values of the sympatho-vagal balance as a value of the interaction of parasympathetic (HF) and sympathetic (LF) and parasympathetic activity (R-MSSD) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Exploratory data analysis of classic heart rate parameters and their correlation to clinical symptoms/patient diary 2) Comparison of sympatho-vagal balance (normal values/healthy (data from OvGU BIO|CONCEPT.ECG library) vs. SARS-CoV-2 in the no longer infectious stage 3) Validation of the applicability of the inZHerz (DRKS0002238) circadian profile 4) Artifact and security analysis | — |
Countries
Germany
Contacts
Public ContactEsther Meyer
Universitätsklinik für Pneumolgie
Outcome results
None listed